An Update of the North American Chapter of the International Society of Pharmacovigilance (NASoP) Maxine Gossell-WilliamsVeronique F. KugenerAbimbola Cole From the ISoP 02 April 2021 Pages: 511 - 513
Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program Philip G. ConaghanEduardo MyslerGerd Burmester Benefit-Risk Assessment Open access 02 February 2021 Pages: 515 - 530
Population-Based Observational Study of Adverse Drug Event-Related Mortality in the Super-Aged Society of Japan Tomoko FunahashiToshihiro KoyamaMitsunobu R. Kano Original Research Article 07 April 2021 Pages: 531 - 539
Identification and Validation of Major Cardiovascular Events in the United Kingdom Data Sources Included in a Multi-database Post-authorization Safety Study of Prucalopride Ana RuigómezEstel PlanaElizabeth B. Andrews Original Research Article Open access 19 February 2021 Pages: 541 - 551
Public Perspectives of Using Social Media Data to Improve Adverse Drug Reaction Reporting: A Mixed-Methods Study Alexander BulcockLamiece HassanWill Dixon Original Research Article Open access 13 February 2021 Pages: 553 - 564
Anticholinergic Activity of Psychotropic Drugs and Cognitive Impairment Among Participants Aged 45 and Over: The CONSTANCES Study Abdelkrim ZiadClaudine BerrThibault Mura Original Research Article 11 February 2021 Pages: 565 - 579
Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry Eline L. GiraudPepijn W. A. ThomasIBDREAM registry Original Research Article Open access 04 February 2021 Pages: 581 - 588
Assessing the Impact on Health of Pharmacovigilance Activities: Example of Four Safety Signals Florence van HunselLaura PetersAgnes Kant Original Research Article 19 February 2021 Pages: 589 - 600
Clinical Utility of Pharmacogenomic Data Collected by a Health-System Biobank to Predict and Prevent Adverse Drug Events Sonam N. ShahRoseann S. GammalDavid W. Bates Original Research Article 23 February 2021 Pages: 601 - 607
Comment on: Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System Michael Auerbach Letter to the Editor 09 April 2021 Pages: 609 - 610
Authors’ Reply to Michael Auerbach’s Comment on: “Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System” Henry TrumboKarolina KaluzaLawrence T. Goodnough Letter to the Editor Open access 09 April 2021 Pages: 611 - 613